measurement. Abnormal DBS results were further validated by (partial) gene sequencing.
RESULTS
Of the 8258 screened records, 660 patients (73 from Group 1; 587 from Group 2) were eligible. Of these, 252 subjects participated to date (67 from Group 1; 185 from Group 2). Initial DBS was abnormal in six subjects (one from Group 1 and fi ve from Group 2), all of whom had normal CK levels. Repeat testing confi rmed abnormal GAA activity in one subject, who was found to have a single mutation (C to T variant in exon 17); another subject with an initially low DBS value was found to have a single mutation (deletion in exon 18). None of the patients had clinical signs of signifi cant muscle weakness.
CONCLUSIONS
In this exploratory study of selected at-risk patients with SDB, DBS screening is feasible. Although heterozygous carriers were identifi ed, no clinical cases of PD were found. Occasional false-positive DBS values do occur, and in all cases results must be interpreted in light of the clinical context. 
